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Objectives: Low-dose aspirin is recommended for prevention of pre-eclampsia in high-risk 
pregnant women. Current doses provide a conservative risk reduction and some individuals 
demonstrate ‘aspirin non-responsiveness’, with insufficient antiplatelet effects. We aimed to 
determine if aspirin non-responsiveness could be identified in women at high risk of pre-
eclampsia and assess for potential associations with placentally-mediated adverse outcomes. 
Study design: Prospective cohort study. 180 women at high-risk of pre-eclampsia, by NICE 
criteria, prescribed 75mg dispersible aspirin daily were recruited from antenatal clinics of 
Liverpool Women’s Hospital between 17/01/14 and 31/03/16. Platelet function (MultiplateTM 
impedance aggregometry, VerifyNowTM and 11-dehydrothromboxane B2) and aspirin 
metabolites (nuclear magnetic resonance and liquid chromatography mass spectrometry) 
were assessed at 5+0-20+6 and 33+0-35+6 weeks. Pearson’s chi-square test was used to 
assess for associations between longitudinal response to aspirin and (1) any pre-eclampsia 
(2) composite adverse placentally-mediated outcome (one, or combination of pre-eclampsia, 
placental abruption, IUGR and perinatal mortality). A Bonferroni correction was applied to 
correct for multiple analyses. 
Results: 180 women were recruited, there were 4 withdrawals and no women were lost to 
follow-up. After 15 women delivered prior to the completion of follow-up, sufficient sample 
volumes for longitudinal platelet function and aspirin adherence testing were obtained from 
156 women. There were no consistent aspirin non-responders in the cohort. 59% (n=92) 
women exhibited normal response to aspirin, 34% (n=53) variable response (switching 
response status between study visits) and in 7% (n=11) response could not be determined as 
they exhibited lack of platelet response on a background of undetectable aspirin metabolites. 
There was no significant association between indeterminate or inconsistent (variable or 
indeterminate) response to aspirin and either pre-eclampsia (p=0.59, p=0.84) or composite 
outcome (p=0.95, p=0.65). 
Conclusions: When platelet function was assessed with COX-specific tests that measure the 
antiplatelet effects of low-dose aspirin and aspirin adherence is accurately accounted for 
aspirin non-responsiveness was not identified in pregnant women at high-risk of pre-
eclampsia. Response to aspirin was not associated with placentally-mediated adverse 
outcomes. The high-degree of variable and indeterminate aspirin response indicates 
suboptimal adherence and/or dosing are more pressing factors to address to optimise aspirin 
effectiveness.  
Keywords: Pregnancy; pre-eclampsia; aspirin; aspirin resistance; aspirin non-
responsiveness 
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 INTRODUCTION  
Low-dose aspirin (LDA) is a safe preventative treatment recommended for women at high-risk 
of pre-eclampsia [1]. LDA confers a relatively modest 10% reduction in the overall risk of pre-
eclampsia, delivery prior to 34 weeks gestation and serious adverse pregnancy outcome [2]. 
Recent evidence suggests that, in carefully selected populations, the reduction in early onset 
pre-eclampsia may be greater than 50% [3]. However, over the last two decades it has 
become apparent that individuals may not have uniform antiplatelet action or clinical effects 
from aspirin. Such inadequate response is referred to interchangeably as aspirin resistance 
and aspirin non-responsiveness [4, 5]. Many causes have been proposed including 
pharmacokinetic, pharmacodynamic and genetic factors, though the most common is 
suboptimal aspirin adherence [4] Aspirin non-responsiveness ranges from 5-65% dependent 
on the platelet function assessment used and definition applied [6-10]. Biochemical aspirin 
non-responsiveness is defined as insufficient suppression of cyclo-oxygenase (COX)-
mediated platelet function in individuals exposed to aspirin, with platelets retaining the ability 
to produce thromboxane A2 (TXA2), a potent pro-platelet aggregator.  This may stem from 
incomplete COX blockade or the production of TXA2 via alternative pathways. Unfortunately, 
there is widespread lack of consensus on an appropriate definition and diagnostic test for 
aspirin non-responsiveness [5]. Clinical definitions of aspirin non-responsiveness focus on 
recurrence of adverse events in aspirin-treated individuals.  
Pregnancy is a state of enhanced platelet turnover, with immature platelets prone to activate 
and aggregate more readily, providing a plausible basis for diminished aspirin responsiveness 
in pregnancy [11]. Several observational studies suggested a direct link between aspirin non-
responsiveness and adverse pregnancy outcomes [12-14]. In these high-risk obstetric 
populations, aspirin non-responsiveness was identified in 29-39% of women and associated 
with a higher risk of pre-eclampsia, preterm birth or of small for gestational age infants [12, 
13]. Additionally, Rey et al undertook PFA-100TM guided aspirin dose escalation and 
demonstrated that where escalation was necessary, women were at increased risk of pre-
eclampsia (11/43, 25.6% vs. 6/68, 8.8%, p = 0.03) [12].  
Our aim was to assess whether aspirin non-responsiveness could be identified in a 
prospectively recruited cohort of aspirin-adherent pregnant women at high-risk of pre-
eclampsia, and if response to aspirin could be linked to placentally-mediated adverse 
pregnancy outcomes. 
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 PARTCIPANTS AND METHODS 
The Estimating Aspirin ResisTance in High-risk women (EARTH) study was a prospective 
cohort study, approved by the Liverpool Research Ethics Committee (13/NW/0764) and 
conducted in high-risk antenatal clinics of Liverpool Women’s Hospital between January 2014 
and March 2016.  
Inclusion and exclusion criteria 
Women viable singleton pregnancies, with at least one high risk factor or at least two moderate 
risk factors for pre-eclampsia and prescribed 75mg dispersible aspirin daily (LDA) were eligible 
for inclusion. (Table 1) Women were excluded if they were prescribed a higher dose of aspirin, 
if they were taking aspirin more than once daily, or if they were prescribed other antiplatelet 
or anticoagulant medication. 
Study procedures 
Maternal whole blood and urine were obtained at two separate visits between 5+0-20+6 and 
33+0 and 35+6 week’s gestation. At each visit, aspirin’s principal plasma (salicylic acid, SA) 
and urinary (salicyluric acid, SUA) metabolites were measured. At 33+0-35+6 week’s additional 
ultrasound examinations of fetal growth (including head and abdominal circumferences, and 
femur length) and Doppler velocimetry of the umbilical artery, middle cerebral artery, ductus 
venosus, and umbilical vein were conducted. All participants were asked to complete aspirin 
diaries for seven days prior to their third trimester visit, reporting the number of omitted doses. 
Laboratory techniques 
Blood samples for platelet function were analysed within 3 hours of collection. Maternal 
plasma and urine samples for measurement of aspirin metabolites were also prepared, 
aliquoted (600µL and 1ml, respectively) and stored at -80oC within 3 hours of collection. The 
platelet function assays used provide COX-selective measures of platelet function that best 
reflect the effects of aspirin.  
 Multiplate™ impedance aggregometry ASPI test (arachidonic acid) (Roche 
Diagnostics Limited, Switzerland) [15] operates with hirudin anticoagulated whole 
blood and is semi-automated for point-of-care use. MultiplateTM detects the change in 
electrical impedance when platelets aggregate on electrode sensors. Change in 
impedance is transformed to aggregation units and plotted against time, to display area 
under the curve (AUC).  
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 VerifyNowTM is a closed point of care system that operates with citrated whole blood. 
VerifyNowTM Aspirin test (arachidonic acid) (Accumetrics, San Diego, CA) [16] 
measures the ability of activated platelets to bind to fibrinogen-coated micro particles. 
Light transmittance increases with the binding of activated platelets, measured as a 
change in optical signal (aspirin reaction units, ARU).  
 TXB CardioTM (Randox, UK) [17] measures urinary 11-dehydrothromboxane B2, a 
stable metabolite of thromboxane A2, production of which is inhibited by aspirin. TXB 
CardioTM is a validated latex enhanced immunoturbidimetric method, with results 
expressed by sample concentration of 11-dehydrothromboxane B2 relative to sample 
creatinine. 
On the day of analysis, urine samples for Nuclear Magnetic Resonance (NMR) spectroscopy 
were thawed and centrifuged (21500 g, 4oC for 5 minutes). Spectra were acquired on a 
700MHz Bruker spectrometer and SUA identified using ChenomxTM pattern recognition 
software (Chenomx, Canada). Plasma aliquots for Liquid Chromatography: Mass 
Spectroscopy (LC: MS) were thawed from -80oC and vortexed for five seconds prior to use. 
SA was identified with high performance LC: MS interfaced with a triple quadruple mass 
spectrometer. LCQUANTM software (Thermo Fisher Scientific, UK) was used for data 
acquisition and processing.  
 
Outcome measures 
MultiplateTM and TXB CardioTM results were assessed against 95% pregnancy-specific 
reference ranges calculated in our laboratory using samples from for healthy pregnant 
volunteers (unpublished). As a pregnancy-specific reference range for VerifyNowTM, is not 
currently available, results were assessed against the manufacturer’s cut-off for normal aspirin 
response (< 550 ARU). Appropriate aspirin adherence was defined as either evidence of 
appropriate platelet response or detection of aspirin metabolites by LC: MS or NMR. Our 
definitions of aspirin response are presented in Table 2.  
Pre-eclampsia and gestational hypertension were defined according to NICE criteria as new 
onset (after 20 weeks) proteinuric or non-proteinuric hypertension, respectively, with systolic 
blood pressure (BP) ≥140 mmHg and/or diastolic BP ≥90mmHg (Korotkoff V) on at least 2 
occasions 4h apart, with proteinuria (spot urine ≥2+, protein: creatinine ratio ≥ 30 mg/mmol, 
or≥ 300 mg/24h using a validated 24 hour collection method). [1] Fetal growth restriction (FGR) 
was defined as customised birthweight < 5th centile [18] with one or more abnormal Doppler 
results (umbilical artery Pulsatility Index >95th centile, reduced, absent, or reversed end 
diastolic flow, middle cerebral artery Pulsatility Index  <5th centile) or post-mortem classification 
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following intrauterine fetal death (IUFD). Composite placentally-mediated adverse outcome 
included pre-eclampsia, placental abruption (identified clinically or with histology), FGR or 
perinatal mortality. 
Statistical analysis 
From previous experience recruiting women at high-risk of pre-eclampsia in our centre we 
ascertained 200 women could feasibly be recruited during a 2 year study period.  We assumed 
12% of participants would develop pre-eclampsia and 20% would be aspirin non-responsive. 
With these assumptions, a sample size of 100 would give good estimated precision for aspirin 
non-responsiveness (i.e. 95% Confidence Intervals from 13%-29%). We hypothesised that 
approximately 40% of aspirin non-responders would develop pre-eclampsia, compared with 
less than 10% of responders.  A sample size of 100 women would have adequate power 
(power of 80% with alpha error of 5%) to test this hypothesis. However, we estimated that a 
total of 180 participants would be required to ensure 100 aspirin adherent women would be 
included in the cohort. 
Data were analysed using SPSS v.24 for Windows (IBM, Chicago, IL). For platelet function 
tests, overall percent agreement (OPA) was calculated by dividing the sum of agreed positives 
plus agreed negatives by the total tests performed. OPA was calculated for the following 
comparisons at both study visits; VerifyNow and Multiplate, VerifyNow and urinary 11-
Dehydrothromboxane B2 and Multiplate and urinary 11-Dehydrothromboxane B2. Descriptive 
statistics for the cohort, including mean and standard deviation or median and mode values, 
as appropriate were calculated for participant characteristics and clinical outcomes.  Pearson’s 
chi-square test was used to assess for associations between longitudinal aspirin response 
status and (1) any pre-eclampsia (2) composite adverse placentally-mediated outcome 
(previously defined). A Bonferroni correction was applied to correct for the effect of multiple 
analyses and the threshold for statistical significance was set at 0.025 (0.05/2). 
RESULTS 
Description of the cohort  
A total of 180 women were recruited to the EARTH study, 177 of whom commenced testing 
for aspirin responsiveness and 156 of whom were available for longitudinal analysis (Figure 
1, Table 3). Four women withdrew from follow-up prior to the third trimester visit as they did 
not wish to proceed with further study procedures. All women that withdrew consented to 
collection of their outcome data. Details for those with fetal losses/deliveries prior to 
completion of follow-up are presented in Table 4. The gestational age range of commencing 
aspirin varied from preconceptual to 18 weeks (median of 10 weeks gestation, Table 3). 85% 
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of participants returned completed aspirin diaries. There was no difference in the number of 
omitted doses reported (mode = 0, range 0-6) for those with detectable aspirin metabolites 
and those where no metabolites were detected. 
 
Agreement between platelet function tests 
There was evidence of good agreement between the two whole blood point-of-care tests, 
VerifyNowTM and Multiplate of 81 and 83% at the first and third trimester study visits, 
respectively. However, agreement between these tests and urinary 11-dehdrothromboxane 
B2 was more limited. OPA at the first visit was 74% and 76% with VerifyNowTM and 
MultiplateTM, respectively, and 72 and 78% at the third trimester visit.  
Response to aspirin 
For 156 participants sampled longitudinally, a large proportion of platelet function assay results 
fell outside the range expected for aspirin-treated individuals. For VerifyNowTM Aspirin test 
28% results were above the manufacturer’s threshold. For MultiplateTM, 29% of results fell 
within the pregnancy-specific reference range at the first visit and 30% at the third trimester 
visit. For TXB CardioTM the percentage of results within the aspirin naive reference range fell 
from 36% at the first to 26% at the third trimester visit.  
Overall, a higher proportion of participants were found to be aspirin responsive at the third 
trimester visit (68% at the first, 76.4% at the third trimester visit). When examining 
longitudinal response to aspirin, the most striking finding was that no participants were 
consistently aspirin non-responsive (Figure 1). Of eleven participants with consistent 
indeterminate response to aspirin, only one had a placentally-mediated adverse outcome. 
Forty seven women had taken aspirin for less than a week prior to the first visit, of the 
remainder 68% (n=74) were aspirin responsive, 22% (n=24) were variable responders and 
10% (n=11) had indeterminate response. Durations of aspirin treatment prior to the first visit 
were equivalent between groups; 1-16 weeks (median = 5 weeks) for responders, 1-13 
weeks (median = 6 weeks) for variable responders and 1-18 (median = 5.5 weeks) for the 
indeterminate group.  
Association with placentally-mediated adverse outcomes  
There were no significant associations between aspirin response and clinical outcomes of pre-
eclampsia or the specified composite of placentally-mediated adverse outcomes. (Table 5) 
This was true both when comparing aspirin responders to those with indeterminate response 
(P=0.948) or to those with inconsistent response (indeterminate responders plus variable 
responders, P=0.645). 
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DISCUSSION 
When sampled at different time-points in pregnancy, women who appear non-responsive to 
aspirin can be identified (Figure 1). In contrast to others [5], we did not identify any woman 
who was consistently aspirin non-responsive.  Most women who were initially non-responsive 
became responsive with continued dosing (Figure 1).  Additionally, there were no significant 
associations between aspirin response and placentally-mediated adverse clinical outcomes.  
There are several important facets to our findings. First, platelet function tests alone cannot 
be used to assess for responsiveness to aspirin. At each time-point a quarter to a third of test 
results fell within the aspirin naïve range. Even when platelet function and aspirin metabolite 
data are combined, due to aspirin’s rapid clearance, it may not always be feasible to assign a 
definitive response. In the EARTH cohort this resulted in an ‘indeterminate’ response group. 
Work by our group to develop protocols to detect stable plasma and urinary aspirin metabolites 
has indicated that metabolites could be reliably detected in healthy volunteers with a dose to 
sampling interval is 8 hours or less (unpublished). The definition of indeterminate response 
means this group may contain individuals with suboptimal adherence both in the short-term 
(as evidenced by lack of aspirin metabolites) and medium-term (as evidenced by lack of 
expected platelet response). Due to the limitations of methods to detect aspirin metabolites, it 
is also feasible that the indeterminate group could contain genuinely non-responsive 
individuals (insufficient platelet response and dose to sampling interval outside the limits for 
the tests).  Indeterminate response could be addressed by strengthening of adherence data, 
either by guiding the timing of aspirin dosing, to ensure the dose-sampling intervals are 
appropriate for detection, or by re-assessing platelet function following directly observed 
dosing.  
Second, the high-degree of variation in individual response to aspirin across time-points is 
likely to reflect issues with platelet exposure to aspirin. Accurate assignment of response to 
aspirin has further important components: i) confirmation of platelet exposure to aspirin 
(adherence) and ii) assessment of platelet response to aspirin measured by platelet function. 
Variable response is most likely to stem from imperfect aspirin use during follow-up, but also 
calls into question the issue of aspirin dosing in pregnancy.  
As EARTH was an observational study there is a possibility of confounding, both by 
recognised and unrecognised factors. Several characteristics, including BMI, diabetes and 
smoking have been reported by non-obstetric observational studies to be associated with 
aspirin non-responsiveness. However, there is a paucity of obstetric data and a lack of robust 
assessments of aspirin adherence in studies to date [5]. The EARTH study should be 
considered a preliminary investigation of aspirin non-responsiveness and we have conducted 
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an exploratory analysis to assess for associations with key clinical outcomes. Verification of 
our negative findings in a large randomised cohort would be desirable, within which there may 
be scope to investigate models to predict platelet and clinical response to aspirin. Whilst it 
remains possible that individuals who are genuinely aspirin non-responsive may be identified 
in larger cohorts, the lack of any cases in our cohort suggests that numbers expected may be 
of insufficient magnitude for aspirin non-responsiveness to be clinically significant at 
population level.  
The significance of optimising aspirin dosing has recently been highlighted by the ASPRE trial 
[3]. In addition to focussing on dose, the trial protocol accounted for evidence of superior risk 
reduction in pre-eclampsia with aspirin commenced prior to 16 week’s gestation and with 
doses scheduled 8 hours after wakening [19]. Participants underwent assessments of aspirin 
adherence with pill counts and interviews. 80% were designated as having ‘good adherence’ 
(≥85% of doses taken) [3]. EARTH included women prescribed and taking aspirin in 
accordance with their clinical care, reflective of current practice in our tertiary centre. However, 
it is feasible that gestational age at the onset of aspirin, duration of reliable treatment and dose 
schedule could influence measurable response to aspirin and should be controlled for in future 
studies. 
Despite recent promising findings regarding aspirin dosing, there is currently a paucity of 
knowledge of pharmacokinetics and pharmacodynamics of aspirin, specific to pregnancy. In 
light of the ASPRE trial [3], there should be further opportunities to assess aspirin 
pharmacokinetics, pharmacodynamics and forgiveness and to strengthen short and long-term 
safety data for different doses. Whilst pharmacokinetic data are likely to be of use in 
determining the optimal safe and effective aspirin dose, evaluation of forgiveness can be 
utilised to define minimal adherence to ensure the intended pharmacodynamic and clinical 
effects and to optimise the use of aspirin in high-risk pregnancies. 
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 Figures/tables caption list 
Table 1. Eligibility criteria based on NICE guidelines [1]. Women were eligible for inclusion 
with a single high-risk factor or ≥2 moderate risk factors.  
High risk factors Moderate risk factors 
Previous hypertensive disease in 
pregnancy 
First pregnancy 
Chronic hypertension Maternal age >40 years 
Pre-existing type 1 or 2 diabetes BMI >35 
Chronic renal disease Pregnancy interval >10 years 
Autoimmune disease  
e.g. Systemic Lupus Erythematosus, 
Antiphospholipid Syndrome 
Family history of pre-eclampsia  
(first-degree relatives) 
 
Table 2. Definitions of aspirin response. 
Responsive  Two or all three platelet function test results outside of 
normal range indicating   
 Above results seen at both visits.  
 Aspirin metabolites may or may not be present. 
Non-responsive  None or only one platelet function test (false positive) 
outside of normal range indicating lack of aspirin effect  
 Above results seen at both visits. 
 Detectable aspirin metabolites must be present.  
Indeterminate 
response 
 None or only one platelet function test (false positive) 
outside of normal range indicating lack of aspirin effect  
 Above results seen at both visits. 
 No detectable aspirin metabolites seen at both visits 
Variable response   The classification of aspirin response changed between 
two visits in the same participant.  
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 Table 3: Demographic characteristics, antenatal and intrapartum care for EARTH participants 
completing study follow-up (n=156). 
*HDU=high dependency unit, ITU=intensive therapy unit. 
 
 Aspirin 
responder 
(n=92) 
Indeterminate 
response 
(n=11) 
Variable 
response  
(n=53) 
Maternal demographic data 
Mean maternal age (SD) 31.4 (5.3) 29.6 (5.3) 31.3 (5.3) 
Mean body mass index (SD) 28.3 (6.6) 29.1 (5.9) 30.9 (7.4) 
Nulliparous 27.2% (n=25) 9.1% (n=1) 13.2% (n=7) 
Smokers 5.4% (n=5) 9.1% (n=1) 17.0% (n=9) 
Ethnicity 
     Caucasian 
     Afro Caribbean 
     Asian 
     Mixed 
     Other 
     Chinese 
 
82.6% (n=76) 
4.3% (n=4) 
4.3% (n=4) 
4.3% (n=4) 
1.1% (n=1) 
3.3% (n=3) 
 
72.7% (n=8) 
18.2% (n=2) 
0.0% (n=0) 
9.1% (n=1) 
0.0% (n=0) 
0.0% (n=0) 
 
83.0% (n=44) 
9.4% (n=5) 
5.7% (n=3) 
1.9% (n=1) 
0.0% (n=0) 
0.0% (n=0) 
Medical co-morbidities 
     Chronic kidney disease 
     Diabetes 
     Hypertension 
 
12.0% (n=11) 
9.8% (n=9) 
28.3 (n=26) 
 
0.0% (n=0) 
18.2% (n=2) 
27.3% (n=3) 
 
5.7% (n=3) 
7.6% (n=4) 
30.2% (n=16) 
Antenatal care 
Median gestational age of commencing 
LDA (range) 
10 (0-16) 10.5 (2-18) 10 (3-17) 
Antihypertensive treatment 32.6% (n=30) 9.1% (n=1) 32.1% (n=17) 
Admissions due to pre-eclampsia, 
gestational hypertension, IUGR 
14.1% (n=13) 0.0% (n=0) 17.0% (n=9) 
Median length of admission (range) 2.0 (1.0-6.0) 0.0 (0.0-0.0) 2.0 (1.0-13.0) 
Intrapartum care 
Admissions to HDU/ITU 4.3% (n=4) 0.0% (n=0) 11.3% (n=6) 
Median length of HDU/ITU admission 
(range) 
1.0 (1.0-1.0) 0.0 (0.0-0.0) 1.0 (1.0-2.0) 
Acute antihypertensive treatment 12.0% (n=11) 0.0% (n=0) 18.9% (n=10) 
Magnesium sulphate treatment 3.3% (n=3) 0.0% (n=0) 9.4% (n=5) 
Spontaneous labour 13.0% (n=12) 18.2% (n=2) 15.1% (n=8) 
Induction of labour 51.1% (n=47) 81.8% (n=9) 50.9% (n=27) 
Delivery outcomes 
Spontaneous preterm birth <37 weeks 3.3% (n=3) 0% (n=0) 9.4% (n=5) 
Caesarean section 51.1% (n=47) 18.2% (n=2) 39.6% (n=21) 
Table 3: Demographic characteristics, antenatal and intrapartum care for EARTH participants 
completing study follow-up (n=156). 
*IUGR=intrauterine fetal growth restriction, HDU=high dependency unit, ITU=intensive 
therapy unit. 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 Table 4. Participants delivered prior to completion of follow-up visits. 
 
Case  Risk factors Aspirin response  
 
Gestation 
at birth 
Clinical outcomes 
1 Previous PE, family 
history of PE 
Responder 22+0 Placental abruption, maternal 
collapse, hysterotomy, fetal loss. 
2 CH, chronic kidney 
disease, 
nulliparous 
Responder 25+0 IUFD, SGA 
3 CH, nulliparous Intermediate 
responder 
26+6 Spontaneous preterm birth, Poor 
neonatal weight gain  
4 CH, chronic kidney 
disease, previous 
PE 
Responder 29+0 Spontaneous preterm birth, 
periventricular leukomalacia. 
5 CH, previous PE, 
BMI>35 
Responder 31+1 Severe PE, EMCS, FGR, MVUP. 
6 CH, previous PE Responder 31+4 Severe PE, EMCS, SGA  
7 CH nulliparous, 
family history of PE 
Non-responder 32+1 Severe PE, EMCS, SGA 
8 Previous PE, 
BMI>35 
Non-responder 32+2 Spontaneous preterm birth, EMCS 
9 CH, previous PE Responder 32+4 Spontaneous preterm birth, EMCS 
10 Diabetes, 
nulliparous, 
BMI>35 
Responder 33+4 Moderate PE, EMCS, HIE grade III, 
MVUP. 
11 Diabetes, 
nulliparous, 
BMI>35 
Responder 33+6 Moderate PE, EMCS  
12 Previous PE Non-responder 34+3 Fetal distress, fetal duodenal atresia, 
EMCS 
13 Chronic kidney 
disease, 
nulliparous 
Responder 35+4 Severe PE, Labour induction, SGA 
 
CH=chronic hypertension, PE=preeclampsia, FGR=fetal growth restriction, IUFD=intrauterine fetal 
death, SGA=small for gestational age, EMCS=emergency caesarean section, MVUP=placental 
histology showing maternal vascular under perfusion, HIE=hypoxic ischaemic encephalopathy. 
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 Table 5. Maternal, fetal and neonatal outcomes. 
 Aspirin 
responder 
(n=92) 
Indeterminate 
response 
(n=11) 
Variable 
response 
(n=53) 
MATERNAL CLINICAL OUTCOMES 
Pre-eclampsia 
≥37 weeks with AGA 
≥37 weeks with SGA 5-9th customised centile 
≥37 weeks with SGA <5th customised centile 
<37 weeks with AGA 
<37 weeks with SGA 5-9th customised centile 
<37 weeks with SGA <5TH customised centile 
<37 weeks with IUGR 
15 (16%) 
8 (9%) 
1 
1 
2 
0 
1 
1 
1 
1 
0 
0 
0 
0 
0 
0 
8 (15%) 
4 (7.5%)  
0 
1 
1 
0 
1 
1 
Gestational hypertension 5 (5%)  0 4 (7.5%)  
Placental abruption 1 0 0 
FETAL AND NEONATAL OUTCOMES 
IUFD 1 0 1 
Isolated FGR 1 1 2 
Isolated SGA 
<5th customised centile 
5-9th customised centile 
11 (12%) 
4 (4%) 
7 (8%) 
1 
0 
1 
6 (11%) 
1 
5 (9%) 
Admissions to NICU  6 (6.5%)  2  10 (19%)  
Median length of NICU admission (range) 1.5 (1.0-11.0) 30.0 (1.0-59.0) 3.0 (1.0-11.0) 
COMPOSITE PLACENTALLY MEDIATED 
ADVERSE OUTCOME 
16 (17%) 2 (18%) 11 (21%) 
*AGA=appropriate for gestational age, SGA=small for gestational age, IUFD=intrauterine fetal death, 
FGR=fetal growth restriction, NICU=neonatal intensive care unit. 
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 Figure 1. EARTH study flow diagram. 
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Figure 2. Participants’ Longitudinal response to aspirin during the EARTH study. 
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